Netherlands · Delayed Price · Currency is EUR Koninklijke Philips Earnings Call Transcripts
Fiscal Year 2026
-
The AGM addressed strong financial progress, new strategic plans, and robust AI-driven innovation, while also tackling shareholder concerns about governance, litigation, and regulatory compliance. All proposals, including dividend and board appointments, were approved by large majorities.
-
Q1 2026 delivered solid growth in orders, sales, and margin expansion, led by North America and Personal Health. Full-year guidance is reiterated despite inflation and geopolitical risks, with productivity and innovation supporting performance.
-
The company is entering a new phase targeting mid-single-digit sales CAGR and mid-teens margins by 2028, driven by segment-specific strategies, accelerated AI-powered innovation, and disciplined execution. Strong growth is expected across all segments, with North America as a key engine and deep customer partnerships supporting platform adoption and operational excellence.
Fiscal Year 2025
-
Q4 and full-year 2025 saw strong order intake, sales, and margin expansion, with robust growth in North America and personal health. 2026 guidance targets 3%-4.5% sales growth and further margin improvement, despite ongoing tariff and macro headwinds.
-
Q3 2025 saw 3% sales growth and 8% order intake growth, with margin expansion despite tariff headwinds. Personal Health led segment growth, while Connected Care and Diagnosis & Treatment also contributed. Outlook for full-year sales and margin remains at the upper end of guidance, with continued focus on productivity and innovation.
-
Order intake grew 6% year-over-year, with strong innovation-driven demand and margin expansion. Sales growth was led by Personal Health, while D&T and Connected Care saw margin improvements despite slight sales declines. Full-year guidance for sales and EBITDA margin was raised, reflecting tariff mitigation and productivity gains.
-
The AGM highlighted strong profitability and innovation progress amid global uncertainty, with all proposals—including a EUR 0.85 dividend, board appointments, and share authorizations—approved by large majorities. Key risks discussed included tariffs, geopolitical tensions, and compliance, while strategic focus remains on regionalization, ESG, and healthcare innovation.
-
Order intake grew 4% excluding China, with strong North America and personal health performance. Sales fell 2% year-over-year, but margins remained resilient due to innovation and productivity. 2025 guidance is unchanged for sales growth, but EBITDA margin is lowered due to tariffs, with mitigations underway.
Fiscal Year 2024
-
Strong profitability and cash flow were delivered in 2024, with growth outside China offsetting declines in China. Margin expansion and innovation momentum continue, with cautious 2025 guidance reflecting ongoing China headwinds and legal settlements.
-
Profitability improved in Q3 2024, with adjusted EBITDA margin up to 11.8% and strong operational execution, despite flat sales and order declines driven by China weakness. Full-year sales outlook was lowered, but margin guidance remains at the upper end, with robust growth outside China.
-
The event detailed a strategy focused on sustainable, impactful healthcare innovation, leveraging leading positions in diagnosis, treatment, and informatics. Emphasis was placed on business-led, scalable innovation, rapid AI adoption, and open, cloud-based platforms, with strong financial, ESG, and talent commitments.
-
Q2 2024 saw 2% sales growth, 9% order intake increase, and margin improvement, with all segments contributing. Guidance for 2024 is reiterated, expecting 3%-5% sales growth and 11%-11.5% EBITDA margin, despite ongoing legal and macro uncertainties.